E-LIB Suche - Ergebnisse für: Vucinic, V.

1

Immunotherapy: IN-DEPTH CHARACTERIZATION OF THE IMMUNE MICR..:

Weirauch, U. ; Alb, M. ; Weiß, R....
Cytotherapy. 25 (2023) 6 - p. S255-S256 , 2023

Link: https://doi.org/10.1016/..

2

STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTA..:

Fricke, S. ; Wang, S. ; Holzhey, T....
Hematological Oncology. 41 (2023) S2 - p. 779-780 , 2023

Link: https://doi.org/10.1002/..

3

An open‐label phase 1/2 study of favezelimab plus pembroliz..:

Lavie, D. ; Johnson, N. ; Borchmann, P....
Hematological Oncology. 41 (2023) S2 - p. 364-366 , 2023

Link: https://doi.org/10.1002/..

4

Axicabtagene ciloleucel (Axicel) for relapsed/refractory pr..:

Schubert, M. ; Ayuk, F. A. ; Bethge, W....
Hematological Oncology. 41 (2023) S2 - p. 411-412 , 2023

Link: https://doi.org/10.1002/..

5

Cellular dynamics and their impact on outcome in patients w..:

Weiss, R. ; Fernandez, C. P. ; Boldt, A....
Hematological Oncology. 41 (2023) S2 - p. 517-518 , 2023

Link: https://doi.org/10.1002/..

6

S287: FACTORS INFLUENCING AUTOLOGOUS LYMPHOCYTE COLLECTIONS..:

Vucinic, V. ; Tumewu, T. ; Brückner, M....
HemaSphere. 6 (2022) - p. 188-189 , 2022

Link: https://doi.org/10.1097/..

7

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKA..:

Herrera, A. F. ; Lavie, D. ; Johnson, N. A....
HemaSphere. 6 (2022) - p. 977-978 , 2022

Link: https://doi.org/10.1097/..

8

P1313: PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY ..:

Jentzsch, M. ; Herrmann, L. ; Bischof, L....
HemaSphere. 6 (2022) - p. 1198-1199 , 2022

Link: https://doi.org/10.1097/..

9

P1356: PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINI..:

Jentzsch, M. ; Bischof, L. ; Backhaus, D....
HemaSphere. 6 (2022) - p. 1241-1242 , 2022

Link: https://doi.org/10.1097/..

10

P509: CLONAL HEMATOPOIESIS-ASSOCIATED MUTATIONS AS MEASURAB..:

Bischof, L. ; Ussmann, J. ; Brauer, D....
HemaSphere. 6 (2022) - p. 408-409 , 2022

Link: https://doi.org/10.1097/..

11

P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED AL..:

Ussmann, J. ; Hell, S. ; Schetschorke, B....
HemaSphere. 6 (2022) - p. 1265-1266 , 2022

Link: https://doi.org/10.1097/..

12

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THER..:

Derigs, P. ; Bethge, W. ; Holtick, U....
HemaSphere. 6 (2022) - p. 1331-1332 , 2022

Link: https://doi.org/10.1097/..

13

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKA..:

Gregory, G. ; Timmerman, J. ; Lavie, D....
HemaSphere. 6 (2022) - p. 976-977 , 2022

Link: https://doi.org/10.1097/..

14

OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR L..:

Dreger, P. ; Martus, P. ; Holtick, U....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

15

Rapid infant weight gain is associated with excess adiposit..:

Flores-Barrantes, P. ; Iglesia, I. ; Miguel-Berges, M. L....
Child and Adolescent Obesity. 4 (2021) 1 - p. 60-77 , 2021

Link: https://doi.org/10.1080/..